S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
NASDAQ:TSHA

Taysha Gene Therapies (TSHA) Price Target & Analyst Ratings

$2.57
-0.31 (-10.76%)
(As of 10/3/2023 ET)
Compare
Today's Range
$2.54
▼
$2.89
50-Day Range
$0.63
▼
$3.66
52-Week Range
$0.50
▼
$3.89
Volume
1.69 million shs
Average Volume
1.98 million shs
Market Capitalization
$480.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.91
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Taysha Gene Therapies Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 12 Analyst Ratings

Consensus Analyst Price Target

$7.91
207.75% Upside
High Prediction$19.00
Average Prediction$7.91
Low Prediction$3.00
TypeCurrent
10/3/22 to 10/3/23		1 Month Ago
9/3/22 to 9/3/23		3 Months Ago
7/5/22 to 7/5/23		1 Year Ago
10/3/21 to 10/3/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
9 Buy rating(s)
10 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$7.91$8.09$7.58$24.20
Predicted Upside207.75% Upside296.01% Upside415.82% Upside341.97% Upside
Get Taysha Gene Therapies Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.


TSHA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TSHA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Taysha Gene Therapies Stock vs. The Competition

TypeTaysha Gene TherapiesMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.66
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside207.75% Upside854.17% Upside701.36% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/20/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$5.00+65.02%
9/20/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$7.00 ➝ $6.00+91.69%
9/20/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$6.00 ➝ $5.00+62.87%
8/15/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMarket Outperform ➝ Market Outperform$4.00+80.90%
8/15/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$5.00+134.74%
8/15/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$6.00 ➝ $8.00+275.59%
8/14/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$2.00 ➝ $7.00+324.55%
2/2/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral
2/1/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold
1/27/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOverweight ➝ Equal Weight$23.00 ➝ $3.00+62.16%
1/4/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight$14.00 ➝ $10.00+354.54%
11/9/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral
11/8/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$22.00 ➝ $19.00+775.57%
(Data available from 10/3/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












TSHA Price Target - Frequently Asked Questions

What is Taysha Gene Therapies's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for Taysha Gene Therapies stock is Moderate Buy based on the current 4 hold ratings and 8 buy ratings for TSHA. The average twelve-month price prediction for Taysha Gene Therapies is $7.91 with a high price target of $19.00 and a low price target of $3.00. Learn more on TSHA's analyst rating history.

Do Wall Street analysts like Taysha Gene Therapies more than its competitors?

Analysts like Taysha Gene Therapies more than other Medical companies. The consensus rating score for Taysha Gene Therapies is 2.67 while the average consensus rating score for medical companies is 2.66. Learn more on how TSHA compares to other companies.

Does Taysha Gene Therapies's stock price have much upside?

According to analysts, Taysha Gene Therapies's stock has a predicted upside of 237.56% based on their 12-month price targets.

What analysts cover Taysha Gene Therapies?

Taysha Gene Therapies has been rated by Canaccord Genuity Group, Cantor Fitzgerald, Chardan Capital, JMP Securities, Needham & Company LLC, Robert W. Baird, and Truist Financial in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:TSHA) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -